{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360004230250144512.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/pbc.24777"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpbc.24777"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.24777"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Neuroblastoma in older children and adolescents has a distinctive, indolent phenotype, but little is known about the clinical and biological characteristics that distinguish this rare subgroup. Our goal was to determine if an optimal age cut‐off exists that defines indolent disease and if accepted prognostic factors and treatment approaches are applicable to older children.</jats:p></jats:sec><jats:sec><jats:title>Procedure</jats:title><jats:p>Using data from the International Neuroblastoma Risk Group, among patients ≥18 months old (n = 4,027), monthly age cut‐offs were tested to determine the effect of age on survival. The prognostic effect of baseline characteristics and autologous hematopoietic cell transplant (AHCT) for advanced disease was assessed within two age cohorts; ≥5 to <10 years (n = 730) and ≥10 years (n = 200).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Older age was prognostic of poor survival, with outcome gradually worsening with increasing age at diagnosis, without statistical evidence for an optimal age cut‐off beyond 18 months. Among patients ≥5 years, factors significantly prognostic of lower event‐free survival (EFS) and overall survival (OS) in multivariable analyses were INSS stage 4, <jats:italic>MYCN</jats:italic> amplification and unfavorable INPC histology classification. Among stage 4 patients, AHCT provided a significant EFS and OS benefit. Following relapse, patients in both older cohorts had prolonged OS compared to those ≥18 months to <5 years (<jats:italic>P</jats:italic> < 0.0001).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Despite indolent disease and infrequent <jats:italic>MYCN</jats:italic> amplification, older children with advanced disease have poor survival, without evidence for a specific age cut‐off. Our data suggest that AHCT may provide a survival benefit in older children with advanced disease. Novel therapeutic approaches are required to more effectively treat these patients. Pediatr Blood Cancer 2014;61:627–635. © 2013 Wiley Periodicals, Inc.</jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004230250144519","@type":"Researcher","foaf:name":[{"@value":"Yaël P. Mossé"}],"jpcoar:affiliationName":[{"@value":"Division of Oncology, Children's Hospital of Philadelphia and Department of Pediatrics Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004230250144644","@type":"Researcher","foaf:name":[{"@value":"Rebecca J. Deyell"}],"jpcoar:affiliationName":[{"@value":"Division of Pediatric Hematology and Oncology British Columbia Children's Hospital, University of British Columbia Vancouver British Columbia Canada"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004230250144520","@type":"Researcher","foaf:name":[{"@value":"Frank Berthold"}],"jpcoar:affiliationName":[{"@value":"Department of Pediatric Hematology and Oncology University of Cologne Cologne Germany"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004230250144515","@type":"Researcher","foaf:name":[{"@value":"Akira Nagakawara"}],"jpcoar:affiliationName":[{"@value":"Chiba Cancer Center Research Institute Chiba Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004230250144518","@type":"Researcher","foaf:name":[{"@value":"Peter F. Ambros"}],"jpcoar:affiliationName":[{"@value":"Children's Cancer Research Institute, St. Anna Kinderspital Vienna Austria"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004230250144769","@type":"Researcher","foaf:name":[{"@value":"Tom Monclair"}],"jpcoar:affiliationName":[{"@value":"Department of Surgery The National Hospital Rikshospitalet Oslo Norway"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004230250144773","@type":"Researcher","foaf:name":[{"@value":"Susan L. Cohn"}],"jpcoar:affiliationName":[{"@value":"University of Chicago School of Medicine Chicago Illinois"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004230250144652","@type":"Researcher","foaf:name":[{"@value":"Andrew D. Pearson"}],"jpcoar:affiliationName":[{"@value":"Institute of Cancer Research Royal Marsden Hospital, Sutton Surrey United Kingdom"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004230250144648","@type":"Researcher","foaf:name":[{"@value":"Wendy B. London"}],"jpcoar:affiliationName":[{"@value":"Boston Children's Hospital and Dana‐Farber Harvard Cancer Center, Harvard Medical School and Children's Oncology Group Statistics and Data Center Boston Massachusetts"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004230250144656","@type":"Researcher","foaf:name":[{"@value":"Katherine K. Matthay"}],"jpcoar:affiliationName":[{"@value":"Department of Pediatrics University of California San Francisco School of Medicine San Francisco California"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"15455009"},{"@type":"EISSN","@value":"15455017"}],"prism:publicationName":[{"@value":"Pediatric Blood & Cancer"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2013-09-13","prism:volume":"61","prism:number":"4","prism:startingPage":"627","prism:endingPage":"635"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpbc.24777"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.24777"}],"createdAt":"2013-09-13","modifiedAt":"2023-10-05","project":[{"@id":"https://cir.nii.ac.jp/crid/1040282257171105280","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"24249061"},{"@type":"JGN","@value":"JP24249061"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-24249061/"}],"notation":[{"@language":"ja","@value":"ヒト神経芽腫ＭＹＣＮ／ＮＣＹＭマウスモデル構築による大規模分子標的創薬"},{"@language":"en","@value":"Generation of the MYCN/NCYM mouse model and the drug discovery for human neuroblastoma"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050866882754445952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clonal evidence for the development of neuroblastoma with extensive copy-neutral loss of heterozygosity arising in a mature teratoma"},{"@value":"Clonal evidence for the development of neuroblastoma with extensive copy‐neutral loss of heterozygosity arising in a mature teratoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145521559168","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neuroblastoma in adolescents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360016862131784576","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Novel TENM3–ALK fusion is an alternate mechanism for ALK activation in neuroblastoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618685228032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neuroblastoma in adolescents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619147891456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Amplification of N-\n            <i>myc</i>\n            in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095409760000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848661808463872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569953100544","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neuroblastoma in adolescents and adults: The Memorial Sloan‐Kettering experience"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570421903232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518562389888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Trends in cancer incidence among children in the U.S."}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519503306496","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519907599616","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neuroblastoma in adults and adolescents"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520074160256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521337354880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Indolent course of advanced neuroblastoma in children older than 6 years at diagnosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944719173120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Response, survival, and toxicity after iodine‐131–metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944824798848","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895250292352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-<i>cis</i>-Retinoic Acid"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896081246848","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study."}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843694725120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Multiagent chemotherapy for children with metastatic neuroblastoma: A report from childrens cancer study group"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319702249856","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neuroblastoma in adolescents: genetic and clinical characterisation"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670321321136896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794519961344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Histopathologic Prognostic Factors in Neuroblastic Tumors: Definition of Subtypes of Ganglioneuroblastoma and an Age-Linked Classification of Neuroblastomas"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794625321728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment."}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269577348608","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271229324544","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neuroblastoma in adults: Incidence and survival analysis based on SEER data"}]},{"@id":"https://cir.nii.ac.jp/crid/1370004230250144768","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neuroblastoma in adolescence and adulthood"}]},{"@id":"https://cir.nii.ac.jp/crid/1370861287993401472","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Characterization of human neuroblastoma cell lines that lack N‐myc gene amplification"}]},{"@id":"https://cir.nii.ac.jp/crid/1390283659848192384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Research on Analysis of Final Diagnosis and Prognostic Factors, and Development of New Therapeutic Drugs for Malignant Tumors (Especially Malignant Pediatric Tumors)"},{"@language":"ja","@value":"悪性腫瘍（特に小児悪性腫瘍）に対する確定診断と予後因子検索とその新規治療薬の研究開発"},{"@language":"ja-Kana","@value":"アクセイ シュヨウ(トクニ ショウニ アクセイ シュヨウ)ニ タイスル カクテイ シンダン ト ヨゴ インシ ケンサク ト ソノ シンキ チリョウヤク ノ ケンキュウ カイハツ"}]},{"@id":"https://cir.nii.ac.jp/crid/1571417124447564928","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Loss of the putative tumor suppressor-gene locus 1p36 as investigated by a PCR-assay and N-myc amplification in 48 neuroblastomas : results of German Neuroblastoma Study Group."},{"@value":"Loss of the putative tumor suppressor‐gene locus 1p36 as investigated by a PCR‐assay and N‐myc amplification in 48 neuroblastomas: Results of the German Neuroblastoma Study Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1573668925044851328","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Detection of N-myc gene amplification by fluorescence in situ hybridization : diagnostic utility for neuroblastoma"},{"@value":"Detection of N‐myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/pbc.24777"},{"@type":"KAKEN","@value":"PRODUCT-14505852"},{"@type":"KAKEN","@value":"PRODUCT-14505829"},{"@type":"CROSSREF","@value":"10.1038/s41388-022-02301-1_references_DOI_EUtrkTrnhsRKWOwKKay4myXtT64"},{"@type":"CROSSREF","@value":"10.1248/yakushi.19-00178_references_DOI_EUtrkTrnhsRKWOwKKay4myXtT64"},{"@type":"CROSSREF","@value":"10.1111/cas.14931_references_DOI_EUtrkTrnhsRKWOwKKay4myXtT64"}]}